Skip to main content

Requirements for Batch Production Records

BayBiotech.NET
Batch Production Record is an example of a GMP document and is designed to standardize the process and provides with lot-specific information.
GMP Requirements for Batch Records are defined under following FDA regulations:
 Master Batch Record 21 CFR 211.188
 21 CFR 211.194—Laboratory Records
 21 CFR 211.194—Review by the Quality Control Unit
A batch production record must be established every time a batch is manufactured and must include the following:
Requirements for Laboratory Operations

•Establish and follow written procedures for laboratory operations
•Use adequate laboratory facilities
•Requirements for Laboratory control processes
•Methods for testing and examination
Requirements for Manufacturing Operations
•Establish and follow written procedures for manufacturing operations
•Ensure product specifications are consistent
•Adequate sanitation principles
•Prevent contamination
•Appropriate disposition of rejected or unsuitable dietary supplements
•Requirements for repackaging and relabeling
•Packaged and labeled supplements rejected for distribution
•Record Keeping
•Establish and follow written procedures for holding and distributing operations
•Requirements to hold components, supplements, packaging and labels
•Requirements for in-process materials
•Requirements for reserve samples
•Distribution requirements to protect against contamination and deterioration

The content produced here are part of the QA/Regulatory training taken from Kriger Research Center.

Comments

Post a Comment

Popular posts from this blog

Good Machine Learning Practices

BayBiotech.NET A joint effort by FDA,  United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have developed guiding principles to help promote utilization of medical devices that are safe and effective and utilize artiificial intelligence and machine learning. To find out more details check out the link here!
Post a Comment
Read more

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...
Post a Comment
Read more

Risk Based Clinical Monitoring

BayBiotech.NET FDA's recommendation of Risk Based Monitoring of Clinical Trials , as published in their Draft Guidance in August 2011. For the first time, FDA provided guidance on monitoring of clinical investigations in 1988 which was recently withdrawn, stated that the “most effective way” to monitor an investigation was to “maintain personal contact between the monitor and the investigator throughout the clinical investigation.” At the time the guidance was issued, sponsors had only limited ways to effect meaningful communication with investigators other than through on-site visits.   This guidance recommends an assessment by the sponsor for the need of 100% on-site monitoring. Such an assessment may be based on the complexity of the study protocol and not be generally applicable to all trial types. It explains the importance of remote monitoring facilitated by the use of electronic data capture system (EDC) and also emphasizes the need of the identifying crit...
1 comment
Read more